<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932529</url>
  </required_header>
  <id_info>
    <org_study_id>NSD-ID10591</org_study_id>
    <nct_id>NCT00932529</nct_id>
  </id_info>
  <brief_title>Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting</brief_title>
  <acronym>BPP</acronym>
  <official_title>Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bergen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite different pharmacological properties, the scientific evidence is inconclusive
      regarding which of the first-line second generation antipsychotics (SGAs) should be preferred
      for the individual patient suffering from psychosis. The limitations of the evidence base may
      be related to the highly selected samples, short duration, and rigid experimental designs of
      most randomized clinical trials of efficacy. Moreover a high proportion of the clinical
      trials are drug company sponsored which could introduce funding bias. The purpose of this
      non-commercially funded study is to investigate whether effectiveness differences exist among
      the first-line SGAs olanzapine, quetiapine, risperidone, and ziprasidone when the drugs are
      used in a representative clinical setting. Eligible patients are those admitted to hospital
      for acute psychosis and candidates for oral antipsychotic treatment. The investigators
      hypothesise that in the naturalistic setting of every-day clinical practice and in a diverse
      sample representative of most patients admitted for symptoms of acute psychosis, differential
      effectiveness among the SGAs could be disclosed when the patients are followed for up to 2
      years. This could deliver valuable information regarding which SGA should be the starting
      antipsychotic drug in order to facilitate the most beneficial outcome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of PANSS total score</measure>
    <time_frame>Admission, discharge/ 6 weeks if not discharged, 3, 6, 12, 24 months after admittance.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>Discharge/ after 6 weeks if not discharged, 3, 6, 12, 24 months after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until initial drug discontinuation</measure>
    <time_frame>Up to 24 months follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ziprasidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_label>Ziprasidone</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.</description>
    <arm_group_label>Quetiapine</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_label>Ziprasidone</arm_group_label>
    <other_name>Zeldox, Geodon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Psychosis

          -  Must be able to use oral antipsychotic drugs

        Exclusion Criteria:

          -  Mania

          -  Unable to cooperate with the assessments

          -  Unable to understand Norwegian language

          -  Candidates for electroconvulsive therapy

          -  Use of Clozapine at admittance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Haukeland University Hospital, Division of Psychiatry</name>
      <address>
        <city>Bergen</city>
        <state>Sandviken</state>
        <zip>N-5035</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2009</study_first_submitted>
  <study_first_submitted_qc>July 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2009</study_first_posted>
  <last_update_submitted>May 24, 2010</last_update_submitted>
  <last_update_submitted_qc>May 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hugo A. JÃ¸rgensen</name_title>
    <organization>University of Bergen</organization>
  </responsible_party>
  <keyword>Antipsychotic drugs</keyword>
  <keyword>Treatment effectiveness</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

